▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #163 by analyst upside · 2026-11-14
BMEA
Biomea Fusion, Inc.
Healthcare · Market Cap $42M · P/E 0x
ANALYST PRICE TARGET
+959.2%
implied upside to consensus target
Current Price $0.58
Consensus Target $6.17
Bull Target $10.0
Bear Target $4.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
0
Sell
1
52-Week Low $0.54
52-Week High $2.24
YTD Return -56.6%
FUNDAMENTALS
Market Cap $42M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.10
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.54
52-Week High $2.24
Current Price $0.58
Bear Target $4.0
Bull Target $10.0
● Now $0.58 ● Target $6.17
TRADING DATA
Avg Volume 2.2M
YTD Return -56.6%
Analyst Count 6
Consensus Buy
Upside to Target +959.2%
Last Updated 2026-11-14

ANALYST SUMMARY

Biomea Fusion, Inc. (BMEA) is currently trading at $0.58 with a Wall Street consensus price target of $6.17, implying potential upside of 959.2% over the next 12 months. 6 analysts currently cover BMEA, with a consensus rating of Buy - 83% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $10.0, while the most cautious has a target of $4.0.

BMEA operates in the Healthcare sector with a market capitalisation of $42M. The stock is down 56.6% year-to-date and is currently trading near the lower end of its 52-week range of $0.54 – $2.24.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BMEA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens reit
Market Outperform → Market Outperform 2026-10-14 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-10-14 31% win rate (48 calls)
Brookline Capital ● Initiated
Buy 2026-10-07 20% win rate (5 calls)
Citizens ● Initiated
Market Outperform 2026-05-05 Building track record
D. Boral Capital - Reiterated
Buy → Buy 2026-04-28 32% win rate (25 calls)
D. Boral Capital - Reiterated
Buy → Buy 2026-04-08 32% win rate (25 calls)
Citigroup - Reiterated
Buy → Buy 2026-03-27 Building track record
D. Boral Capital - Reiterated
Buy → Buy 2026-03-25 32% win rate (25 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
37
out of 100
Coverage depth
15/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →